Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Treatment of Relapsed/Refractory CML

January 13th 2017

Relapse After CML Treatment Discontinuation

January 13th 2017

The NILSt and D-STOP Trials in CML

January 13th 2017

Treatment-Free Remission in CML

January 13th 2017

Managing Toxicities from BCR-ABL TKIs in CML

January 13th 2017

Monitoring Response to CML Therapy

January 13th 2017

Early Molecular Responses in CML

January 13th 2017

Treatment Choice in CML

January 13th 2017

TIDEL-II Trial for CML

January 13th 2017

Diagnosis and Upfront Therapy for CML

January 13th 2017

Dr. Neelapu on the Safety Profile of KTE-C19 in Patients With Lymphoma

January 12th 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.

Landscape for Myeloproliferative Disorders Becoming More Defined With Improved Treatments, Biomarkers

January 11th 2017

Emerging therapies in myeloproliferative disorders such as chronic myeloid leukemia, polycythemia vera, and myelofibrosis could have the potential to shake up the landscape.

Emerging Therapies for Acute Myeloid Leukemia

January 11th 2017

Venetoclax in AML

January 11th 2017

Vosaroxin/Cytarabine in AML

January 11th 2017

IDH1/2 inhibitors for AML

January 11th 2017

Quizartinib in AML

January 11th 2017

Emerging Role of FLT3 Inhibitors in AML: Midostaurin

January 11th 2017

Maintenance Therapy for AML

January 11th 2017

MRD Assessment and Consolidation in AML

January 11th 2017